Riddhi Siddhi Gluco Biols Falls to 52-Week Low of Rs.451.2 Amidst Continued Downtrend

Stock Price Movement and Market Context

On 17 Dec 2025, Riddhi Siddhi Gluco Biols recorded an intraday low of Rs.451.2, representing a 5.38% drop during the trading session. This level marks the lowest price point for the stock in the past year, down from its 52-week high of Rs.700. Over the last two trading days, the stock has declined by 7.35%, signalling a continuation of recent negative momentum. The day’s performance also lagged behind the Trading & Distributors sector by 4.42%, indicating relative weakness within its industry group.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a persistent bearish trend without immediate signs of reversal. In contrast, the broader Sensex index, despite a volatile session, remains near its 52-week high and trades above its 50-day and 200-day moving averages, highlighting a divergence between the company’s stock and the overall market.

Financial Performance and Growth Trends

Riddhi Siddhi Gluco Biols has exhibited a negative compound annual growth rate (CAGR) of 14.03% in net sales over the past five years. This long-term contraction in revenue contrasts with the broader market’s positive trajectory. The company’s net sales for the most recent quarter stood at Rs.32.10 crores, reflecting a decline of 34.36% compared to prior periods. Earnings before interest and taxes (EBIT) to interest ratio averaged at -1.18, indicating challenges in covering interest expenses from operating profits.

Profit after tax (PAT) for the nine-month period was Rs.27.63 crores, showing a contraction of 61.36%. The company has reported losses for three consecutive quarters, with profit before tax excluding other income (PBT less OI) at Rs.-4.05 crores, a fall of 225.00%. These figures underscore the financial strain the company is experiencing, with negative returns on capital employed (ROCE) further highlighting the lack of profitability.

Valuation and Risk Considerations

The stock’s valuation appears elevated relative to its historical averages, contributing to a perception of increased risk. Over the past year, Riddhi Siddhi Gluco Biols has generated a return of -28.93%, underperforming the Sensex, which recorded a positive return of 4.71% during the same period. The company’s earnings have also contracted by 18.7% over the last year, reinforcing concerns about its financial health.

In addition to recent performance, the stock has underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months. This consistent underperformance relative to broader market benchmarks reflects ongoing challenges in both the near and long term.

Shareholding and Market Position

The majority shareholding in Riddhi Siddhi Gluco Biols remains with the promoters, indicating concentrated ownership. The company operates within the Trading & Distributors sector, which has seen mixed performance in recent months. Despite the broader market’s resilience, the company’s stock has not mirrored this trend, instead moving to new lows.

Summary of Key Metrics

To summarise, Riddhi Siddhi Gluco Biols’ stock price has reached Rs.451.2, its lowest level in 52 weeks, following a series of declines over recent sessions. The company’s financial indicators reveal contraction in sales and profits, with negative returns on capital and challenges in servicing debt. The stock’s performance contrasts with the broader market’s relative strength, as the Sensex trades near its yearly highs.

While the company remains under pressure, the detailed financial data and market context provide a comprehensive view of its current standing within the Trading & Distributors sector.

Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →